Media Coverage

Endpoint News

Merck makes first big splash for Alzheimer's drug R&D since 2017 fail, inking research pact with Cerevance

PharmaTimes

Positive results for Cerevance’s Parkinson’s drug

BioSpace

With positive phase II results, Cerevance proves concept in Parkinson’s

pharmaphorum

After ph2 win, Cerevance preps pivotal trials of novel Parkinson’s drug

BioSpace

Trial drug shows promise in treating cognitive impairment associated with schizophrenia

Technology Networks

Developing novel treatments for CNS diseases

PM360

Cerevance is exploring the brain at depths never before possible

Cambridge Independent

Cerevance adapts Cambridge Science Park office to safeguard against Covid-19 with help from COEL

AARP

Will we ever find a cure for dementia?

Fierce Biotech

Gates, GV chip into $45M round for CNS biotech Cerevance

Big4Bio

Spotlight: Cerevance raises $45 million to advance therapeutics against novel CNS targets

Pharmaceutical Technology

Breakthrough in neurodegeneration: GV, Bill Gates and Foresite invest $45M in Cerevance

Longevity Technology

Cerevance raising $60m for brain disease drug discovery

Pharmafocus

Working Life column featuring CEO of Cerevance, Brad Margus

BioSpace

Improving how neurological drugs are developed using cell-type-specific analysis

Fierce Biotech

Cerevance gains a new drug discovery chief as another AstraZeneca executive jumps ship

The Bio Report

Targeting the right proteins to treat neurological diseases

BioCentury

Cerevance’s human element: HOW CEREVANCE’S PLATFORM IDENTIFIES CIRCUIT-SPECIFIC CNS TARGETS

The Rockefeller University

New method for studying gene expression could improve understanding of brain disease

View Press Releases